Company: PRME
Filing Date: 2025-05-19
Form Type: 8-K
Source: 0001193125-25-122156
Chunk: 6

Company: Prime Medicine, Inc.
Filing Date: 2025-05-19
Form: 8-K
Item: Item 5.02
Chunk 6
---
 innovation, ensure the broadest application of Prime Editing, and further bolster its financial resources.

CGD Data Update

On May 19, 2025, the Company announced positive initial data from the first patient dosed in its ongoing Phase 1/2 clinical study of PM359 in CGD. Preliminary results from the first patient demonstrated that PM359 was well-tolerated, showed rapid engraftment and restored NADPH oxidase activity to well above the threshold for clinical benefit, as measured by the dihydrorhodamine (“ DHR”) assay. PM359 is being evaluated in a Phase 1/2,